Aviance Capital Partners LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 28.4% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 99,695 shares of the biopharmaceutical company's stock after selling 39,581 shares during the period. Aviance Capital Partners LLC's holdings in Pfizer were worth $2,526,000 as of its most recent filing with the SEC.
Several other institutional investors also recently added to or reduced their stakes in PFE. Norges Bank bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $2,328,986,000. Starboard Value LP acquired a new position in Pfizer in the fourth quarter worth $407,730,000. Raymond James Financial Inc. bought a new stake in shares of Pfizer during the fourth quarter worth $274,694,000. Assenagon Asset Management S.A. raised its position in shares of Pfizer by 307.5% during the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after acquiring an additional 7,581,030 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after acquiring an additional 5,350,381 shares during the last quarter. 68.36% of the stock is owned by institutional investors.
Pfizer Price Performance
Pfizer stock traded up $0.13 during mid-day trading on Friday, reaching $25.45. 27,104,580 shares of the company were exchanged, compared to its average volume of 41,625,077. The company has a fifty day simple moving average of $23.67 and a 200-day simple moving average of $24.84. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The firm has a market cap of $144.66 billion, a PE ratio of 18.44, a PEG ratio of 0.92 and a beta of 0.58.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the company earned $0.82 EPS. The company's revenue was down 7.8% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.76%. Pfizer's payout ratio is 124.64%.
Analysts Set New Price Targets
PFE has been the subject of a number of recent analyst reports. Leerink Partners dropped their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. The Goldman Sachs Group upped their price objective on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Citigroup increased their price objective on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Finally, Wolfe Research upped their price objective on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $28.55.
Check Out Our Latest Stock Analysis on Pfizer
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
